Notwithstanding major advances in psychotherapeutics, their efficacy and specificity remain limited. The slow onset of beneficial outcomes and numerous adverse effects of widely used medications remain of chief concern, warranting in-depth studies. The majority of frontline therapies are thought to enhance the endogenous monoaminergic drive, to initiate a cascade of molecular events leading to lasting functional and structural plasticity. They also involve alterations in trophic factor signalling, including brain-derived neurotrophic factor (BDNF), VGF (non-acronymic), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), glial cell-derived neurotrophic factor (GDNF), and others. In several major mental disorders, emerging data suggest protective and restorative effects of trophic factors in preclinical models, when applied on their own. Antidepressant outcomes of VGF and FGF2, for instance, were shown in experimental animals, while BDNF and GDNF prove useful in the treatment of addiction, schizophrenia, and autism spectrum disorders. The main challenge with the effective translation of these and other findings in the clinic is the knowledge gap in action mechanisms with potential risks, as well as the lack of effective platforms for validation under clinical settings. Herein, we review the state-of-the-art and advances in the therapeutic use of trophic factors in several major neuropsychiatric disorders.

Department of Experimental Neurobiology National Institute of Mental Health Topolová 748 250 67 Klecany Czech Republic

Institute of Experimental Endocrinology Biomedical Research Center Slovak Academy of Sciences Bratislava Slovakia

Institute of Molecular Physiology and Genetics Center of Biosciences Slovak Academy of Sciences Bratislava Slovakia

School of Psychological Sciences and the Sagol School of Neuroscience Tel Aviv University Tel Aviv Israel

000      

00000naa a2200000 a 4500

001      

bmc22012024

003      

CZ-PrNML

005      

20220506130131.0

007      

ta

008      

220425s2021 ie f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.neulet.2021.136194 $2 doi

035    __

$a (PubMed)34433100

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ie

100    1_

$a Dremencov, Eliyahu $u Institute of Molecular Physiology and Genetics, Center of Biosciences, Slovak Academy of Sciences, Bratislava, Slovakia. Electronic address: Eliyahu.Dremencov@savba.sk

245    10

$a Trophic factors as potential therapies for treatment of major mental disorders / $c E. Dremencov, D. Jezova, S. Barak, J. Gaburjakova, M. Gaburjakova, V. Kutna, SV. Ovsepian

520    9_

$a Notwithstanding major advances in psychotherapeutics, their efficacy and specificity remain limited. The slow onset of beneficial outcomes and numerous adverse effects of widely used medications remain of chief concern, warranting in-depth studies. The majority of frontline therapies are thought to enhance the endogenous monoaminergic drive, to initiate a cascade of molecular events leading to lasting functional and structural plasticity. They also involve alterations in trophic factor signalling, including brain-derived neurotrophic factor (BDNF), VGF (non-acronymic), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), glial cell-derived neurotrophic factor (GDNF), and others. In several major mental disorders, emerging data suggest protective and restorative effects of trophic factors in preclinical models, when applied on their own. Antidepressant outcomes of VGF and FGF2, for instance, were shown in experimental animals, while BDNF and GDNF prove useful in the treatment of addiction, schizophrenia, and autism spectrum disorders. The main challenge with the effective translation of these and other findings in the clinic is the knowledge gap in action mechanisms with potential risks, as well as the lack of effective platforms for validation under clinical settings. Herein, we review the state-of-the-art and advances in the therapeutic use of trophic factors in several major neuropsychiatric disorders.

650    _2

$a zvířata $7 D000818

650    _2

$a modely nemocí na zvířatech $7 D004195

650    _2

$a preklinické hodnocení léčiv $7 D004353

650    _2

$a lidé $7 D006801

650    _2

$a duševní poruchy $x farmakoterapie $7 D001523

650    12

$a nanočásticový lékový transportní systém $7 D000090783

650    _2

$a neurotrofní faktory $x aplikace a dávkování $7 D009414

650    _2

$a neuroplasticita $x účinky léků $7 D009473

650    _2

$a přehledová literatura jako téma $7 D012196

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Jezova, Daniela $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia

700    1_

$a Barak, Segev $u School of Psychological Sciences and the Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel

700    1_

$a Gaburjakova, Jana $u Institute of Molecular Physiology and Genetics, Center of Biosciences, Slovak Academy of Sciences, Bratislava, Slovakia

700    1_

$a Gaburjakova, Marta $u Institute of Molecular Physiology and Genetics, Center of Biosciences, Slovak Academy of Sciences, Bratislava, Slovakia

700    1_

$a Kutna, Viera $u Department of Experimental Neurobiology, National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic

700    1_

$a Ovsepian, Saak V $u Department of Experimental Neurobiology, National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic

773    0_

$w MED00003507 $t Neuroscience letters $x 1872-7972 $g Roč. 764, č. - (2021), s. 136194

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34433100 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506130123 $b ABA008

999    __

$a ok $b bmc $g 1789562 $s 1163225

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 764 $c - $d 136194 $e 20210822 $i 1872-7972 $m Neuroscience letters $n Neurosci. lett. $x MED00003507

LZP    __

$a Pubmed-20220425